The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

November 03, 2023 12:10 PM HKT | By Cision
 The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan
Image source: Kalkine Media

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao, Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, industrial associations, pharmaceutical enterprises, etc.

The 2nd Boao International Conference on Real World Studies of Medical Products
The 2nd Boao International Conference on Real World Studies of Medical Products

The conference featured a plenary session and eight sub-forums, and encompassed various fields related to international real-world research, and the scientific development of pharmaceutical product regulation. The topics covered real-world research, drug regulation, pharmaceutical instrument regulation, traditional Chinese medicine regulation, biostatistics, as well as economics. The conference provided a platform for exchanges and innovations of real-world data research and pharmaceutical product regulatory practices, offering new methods, standards and pathways for advancing the role of real-world research of pharmaceutical products in regulatory decision-making across China and the whole globe.

It's worth noting that the National Medical Products Administration and the Hainan provincial government jointly initiated a pilot project for the application of clinical real-world data in June 2019. In the meantime, the Hainan Boao Lecheng International Medical Tourism Pilot Zone (Lecheng Pilot Zone) has been actively collecting real-world evidences and researching to explore how to assist the regulatory decision-making, offering new methods for the reform of the national evaluation system of pharmaceutical products. Nowadays, the real-world research in the Lecheng Pilot Zone has stepped on a fast track, largely matching the international advanced level in pharmaceutical technology, instrument and drugs. It has become a key channel to accelerate the market entry of innovative international pharmaceutical products to China.

According to Deputy Director of Biostatistics and Epidemiology, Real World Evidence Department, Merck, Germany, Real world study is a significant institutional innovation in the Hainan Free Trade Port. "We learnt that four drugs and nine medical devices have been approved by National Medical Products Administration (NMPA) using Real World Data(RWD) from Hainan Boao Lecheng. We look forward to seeing more advances made in this field in China."

To date, the Lecheng Pilot Zone has 26 operational medical institutions and has established extensive and deep collaborations with over 170 pharmaceutical product enterprises from 20 countries and regions, importing more than 350 critically-needed pharmaceutical products.

Image Attachments Links:
Link: https://iop.asianetnews.net/view-attachment?attach-id=443011
Caption: The 2nd Boao International Conference on Real World Studies of Medical Products


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.